EGIS-7625
EGIS-7625 is a selective and competitive 5-HT2B receptor antagonist. It is experimentally proven to be directly associated with smooth stomach muscle construction of white rats in vivo, and variably effective in provoking a similar response in in vitro human stomach cells. In high blood concentrations, it causes mild constriction of rabbit pulmonary arteries.[1]
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C18H22N4O2 |
Molar mass | 326.400 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
References
- Kovács, Anikó; Gacsályi, Istvan; Wellmann, János; Schmidt, Éva; Szücs, Zsuzsanna; Dubreuil, Valérie; Nicolas, Jean Paul; Boutin, Jean; et al. (2003). "Effects of EGIS-7625, a Selective and Competitive 5-HT2B Receptor Antagonist". Cardiovascular Drugs and Therapy. 17 (5/6): 427–34. doi:10.1023/B:CARD.0000015857.96371.43. PMID 15107597.
Simple piperazines (no additional rings) |
|
---|---|
Phenylpiperazines |
|
Benzylpiperazines | |
Diphenylalkylpiperazines (benzhydrylalkylpiperazines) |
|
Pyrimidinylpiperazines |
|
Pyridinylpiperazines |
|
Benzo(iso)thiazolylpiperazines | |
Tricyclics (piperazine attached via side chain) |
|
Others/Uncategorized |
|
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.